A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when immunised four weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Protection achievable with 2-week gap before early delivery
- Vaccination in the third trimester still provides significant infant protection
Compelling evidence from the latest research
The performance of the pregnancy RSV vaccine has been demonstrated through a thorough investigation carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and expectant parents with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers did not receive the vaccination. This marked difference emphasises the vaccine’s vital importance in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine performs when given across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for infected babies to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests heaving as they try to pull adequate oxygen into their damaged lungs. Whilst the majority of babies improve through supportive care, a modest yet notable group succumb from respiratory syncytial virus complications each year, making prevention through vaccination a essential public health priority for protecting the youngest and most vulnerable members of society.
- RSV produces lung inflammation, leading to serious respiratory problems in infants
- Nearly 50% of infants contract the infection during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies die from RSV related complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have emphasised the importance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The communication from health authorities remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These regional differences demonstrate variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to engage with women during pregnancy
- Geographic variations in immunisation take-up across England require targeted improvement
- Community health services tailoring initiatives to suit community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s outstanding effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the introduction of this safeguarding intervention, the 80% reduction in admissions represents thousands of infants shielded from critical disease. Parents no longer face the troubling prospect of seeing their babies gasping for air or labour to feed, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the terrain of neonatal lung health, offering expectant mothers a proactive tool to shield their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in devastating brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to women in pregnancy during their final trimester, converting what was once an inevitable seasonal threat into a manageable health risk.